Coordinated program to develop new treatments for liver cancer
Administrative Core
Researchers are developing new treatment approaches aimed at people with hepatocellular carcinoma (a common form of liver cancer).
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project ID | NIH-11159513 on NIH RePORTER |
What this research studies
This program brings together scientists and clinicians focused on hepatocellular carcinoma to create and refine new therapies. Teams use laboratory experiments and mouse models, test immune-based treatments and nanoparticle drug delivery, and optimize chemical compounds to improve effectiveness. A biostatistics and bioinformatics core analyzes results while an administrative core coordinates the projects and shared resources. The goal is to move promising lab findings into Phase I/II clinical trials where patients can enroll.
Who could benefit from this research
Good fit: In the future, patients with hepatocellular carcinoma—especially those with advanced disease or cancers that have not responded to current treatments—would be the most likely candidates for early-phase trials resulting from this work.
Not a fit: People without liver cancer or those whose disease is already cured by surgery are unlikely to benefit directly from these pre-clinical activities.
Why it matters
Potential benefit: If successful, this work could produce new treatment options for people with hepatocellular carcinoma and speed the start of early clinical trials.
How similar studies have performed: Immunotherapies and nanoparticle drug delivery have shown promise in several cancers, but combining these approaches for hepatocellular carcinoma is still emerging and partly experimental.
Where this research is happening
Richmond, United States
- Virginia Commonwealth University — Richmond, United States (Active)
Researchers
- Principal investigator: Sarkar, Devanand — Virginia Commonwealth University
- Study coordinator: Sarkar, Devanand
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.